Journal Watch · Frontiers in Immunology · 2026
Severe thrombocytopenia is associated with arterial thrombotic manifestations in antiphospholipid syndrome: a two-center cohort study.
PLT <50×10<sup>9</sup>/L may provide additional clinical risk information but may also reflect cumulative disease burden and overall APS severity.
TL;DR
PLT <50×10<sup>9</sup>/L may provide additional clinical risk information but may also reflect cumulative disease burden and overall APS severity.
Key findings
- After multivariable adjustment, PLT <50×10<sup>9</sup>/L remained associated with a higher prevalence of arterial thrombosis (aOR 2.16, 95% CI 1.07-4.35, <i>P</i> = 0.032) and cerebral infarction (aOR 2.37, 95% CI 1.18-4.73, <i>P</i> = 0.015).
- During 48-month follow-up, PLT <50×10<sup>9</sup>/L was associated with increased risks of any thrombotic event (HR 3.28, 95% CI 1.54-6.97, <i>P</i> = 0.002), arterial thrombotic event (HR 3.95, 95% CI 1.39-11.21, <i>P</i> = 0.010), and cerebral infarction (HR 4.11, 95% CI 1.44-11.73, <i>P</i> = 0.008), but not venous-related events.<h4>Conclusion</h4>Severe thrombocytopenia was associated with arterial thrombotic manifestations in APS, particularly cerebral infarction.
- PLT <50×10<sup>9</sup>/L may provide additional clinical risk information but may also reflect cumulative disease burden and overall APS severity.
Numbers at a glance (from the abstract)
Every figure above is taken verbatim from the abstract below. Check the full text for denominators, confidence intervals and subgroup detail.
What they did
Associations with prevalent baseline thrombotic manifestations were assessed using multivariable logistic regression in 300 patients with primary APS or systemic lupus erythematosus-associated APS. In the Renji follow-up cohort (n=254), 48-month thrombotic events were evaluated using Kaplan-Meier curves and Cox models.<h4>Results</h4>PLT <50×10<sup>9</sup>/L was associated with a higher frequency of arterial thrombosis (66.7%), particularly cerebral infarction (62.7%), whereas venous thrombosis was most frequent in the PLT 50-<100×10<sup>9</sup>/L group (68.4%).
Full abstract (original)
Background: <h4>Objective</h4>Thrombocytopenia in APS is often regarded primarily as a bleeding-related manifestation, but the relationship between platelet-count severity and thrombotic manifestations remains uncertain. We evaluated the association between severe thrombocytopenia and arterial thrombotic manifestations in patients with antiphospholipid syndrome (APS).<h4>Methods</h4>In a two-center baseline cohort of 313 patients with APS, baseline platelet count (PLT) was categorized as PLT <50×10<sup>9</sup>/L, PLT 50-<100×10<sup>9</sup>/L, or PLT ≥100×10<sup>9</sup>/L.
What they did: Associations with prevalent baseline thrombotic manifestations were assessed using multivariable logistic regression in 300 patients with primary APS or systemic lupus erythematosus-associated APS. In the Renji follow-up cohort (n=254), 48-month thrombotic events were evaluated using Kaplan-Meier curves and Cox models.<h4>Results</h4>PLT <50×10<sup>9</sup>/L was associated with a higher frequency of arterial thrombosis (66.7%), particularly cerebral infarction (62.7%), whereas venous thrombosis was most frequent in the PLT 50-<100×10<sup>9</sup>/L group (68.4%).
Results & conclusions: After multivariable adjustment, PLT <50×10<sup>9</sup>/L remained associated with a higher prevalence of arterial thrombosis (aOR 2.16, 95% CI 1.07-4.35, <i>P</i> = 0.032) and cerebral infarction (aOR 2.37, 95% CI 1.18-4.73, <i>P</i> = 0.015). During 48-month follow-up, PLT <50×10<sup>9</sup>/L was associated with increased risks of any thrombotic event (HR 3.28, 95% CI 1.54-6.97, <i>P</i> = 0.002), arterial thrombotic event (HR 3.95, 95% CI 1.39-11.21, <i>P</i> = 0.010), and cerebral infarction (HR 4.11, 95% CI 1.44-11.73, <i>P</i> = 0.008), but not venous-related events.<h4>Conclusion</h4>Severe thrombocytopenia was associated with arterial thrombotic manifestations in APS, particularly cerebral infarction. PLT <50×10<sup>9</sup>/L may provide additional clinical risk information but may also reflect cumulative disease burden and overall APS severity.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1927065 · PubMed 42718924.
Why it matters for pharma & biotech
- Relevant to Immunology teams tracking Frontiers in Immunology for new targets, mechanisms and biomarkers.
- Because it reports human data, it can inform indication, endpoint and comparator decisions faster than preclinical work.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
Frequently asked questions
What did this Frontiers in Immunology study find?
PLT <50×10<sup>9</sup>/L may provide additional clinical risk information but may also reflect cumulative disease burden and overall APS severity.
What type of study is this?
It is a cohort / observational clinical study, published in Frontiers in Immunology in 2026. Associations with prevalent baseline thrombotic manifestations were assessed using multivariable logistic regression in 300 patients with primary APS or systemic lupus erythematosus-associated APS.
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1927065. PubMed ID: 42718924. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/severe-thrombocytopenia-is-associated-with-arterial-thrombotic-manifesta-927065/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides